Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.
作者信息
Lewis Edmund J
出版信息
BMJ. 2005 May 28;330(7502):1269-70; author reply 1270-1. doi: 10.1136/bmj.330.7502.1269-a.
Abstract
摘要
相似文献
1
Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.血管紧张素受体阻滞剂与心肌梗死：结果反映了1型和2型糖尿病患者不同的心血管状态。
BMJ. 2005 May 28;330(7502):1269-70; author reply 1270-1. doi: 10.1136/bmj.330.7502.1269-a.
2
Angiotensin receptor blockers and myocardial infarction: analysis of evidence is incomplete and inaccurate.血管紧张素受体阻滞剂与心肌梗死：证据分析不完整且不准确。
BMJ. 2005 May 28;330(7502):1269; author reply 1270-1. doi: 10.1136/bmj.330.7502.1269.
3
Angiotensin receptor blockers and myocardial infarction: direct comparative studies are needed.血管紧张素受体阻滞剂与心肌梗死：需要进行直接对比研究。
BMJ. 2005 May 28;330(7502):1270; author reply 1270-1. doi: 10.1136/bmj.330.7502.1270.
4
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂治疗糖尿病肾病的回顾性比较。
J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):195-200. doi: 10.1177/1470320309352352.
5
[Hypertension therapy for type 2 diabetics].[2型糖尿病的高血压治疗]
MMW Fortschr Med. 2007 Jun 7;149(23):45, 47-8.
6
Diabetes complications and the renin-angiotensin system.糖尿病并发症与肾素-血管紧张素系统
N Engl J Med. 2009 Jul 2;361(1):83-5. doi: 10.1056/NEJMe0904293.
7
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂在心肌梗死、中风和死亡风险方面的比较：一项荟萃分析。
J Hypertens. 2008 Jul;26(7):1282-9. doi: 10.1097/HJH.0b013e328306ebe2.
8
Angiotensin receptor blockers and myocardial infarction: cautions voiced are biologically credible.血管紧张素受体阻滞剂与心肌梗死：所表达的警示在生物学上是可信的。
BMJ. 2005 May 28;330(7502):1270; author reply 1270-1. doi: 10.1136/bmj.330.7502.1270-a.
9
ARBs vs ACE inhibitors for preventing diabetic nephropathy.血管紧张素Ⅱ受体阻滞剂与血管紧张素转换酶抑制剂预防糖尿病肾病的比较
J Fam Pract. 2005 May;54(5):453; discussion 453-4.
10
FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.FPIN临床咨询。糖尿病肾病患者的血管紧张素阻断治疗。
Am Fam Physician. 2007 Aug 1;76(3):423-4.
引用本文的文献
1
A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.血管紧张素受体阻滞剂和直接肾素抑制剂安全性的当前评估。
Vasc Health Risk Manag. 2011;7:297-313. doi: 10.2147/VHRM.S15541. Epub 2011 May 19.
本文引用的文献
1
Angiotensin receptor blockers and myocardial infarction.血管紧张素受体阻滞剂与心肌梗死
BMJ. 2004 Nov 27;329(7477):1248-9. doi: 10.1136/bmj.329.7477.1248.
2
Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.血管紧张素转换酶抑制剂和血管紧张素II受体拮抗剂对糖尿病肾病患者死亡率和肾脏结局的影响：系统评价
BMJ. 2004 Oct 9;329(7470):828. doi: 10.1136/bmj.38237.585000.7C. Epub 2004 Sep 30.
3
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.厄贝沙坦治疗2型糖尿病伴显性肾病患者的糖尿病肾病试验中的心血管结局
Ann Intern Med. 2003 Apr 1;138(7):542-9. doi: 10.7326/0003-4819-138-7-200304010-00010.
4
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.血管紧张素受体拮抗剂厄贝沙坦对2型糖尿病肾病患者的肾脏保护作用。
N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303.
5
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.血管紧张素转换酶抑制对糖尿病肾病的影响。协作研究组。
N Engl J Med. 1993 Nov 11;329(20):1456-62. doi: 10.1056/NEJM199311113292004.
Zotero 插件